The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Arritlan     (3-hydrazinyl-4,5,9- triazabicyclo[4.4.0]de...

Synonyms: Miretilan, ENDRALAZINE, Endralazina, Endralazinum, CHEMBL254193, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of BQ 22-708

 

High impact information on BQ 22-708

 

Chemical compound and disease context of BQ 22-708

 

Biological context of BQ 22-708

 

Associations of BQ 22-708 with other chemical compounds

 

Gene context of BQ 22-708

 

Analytical, diagnostic and therapeutic context of BQ 22-708

References

  1. Endralazine in treatment of hypertension in children with renal disease. Donaldson, M.D., Chambers, T.L. Lancet (1983) [Pubmed]
  2. Long-term beneficial effects of endralazine, a new arteriolar vasodilator at rest and during exercise capacity in chronic congestive heart failure. Quyyumi, A.A., Wagstaff, D., Evans, T.R. Am. J. Cardiol. (1984) [Pubmed]
  3. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs. Salzmann, R., Gerber, W., Pally, C., Scholtysik, G. J. Pharm. Pharmacol. (1983) [Pubmed]
  4. Evaluation of once daily endralazine in hypertension. Wu, R., Spence, J.D., Carruthers, S.G. Eur. J. Clin. Pharmacol. (1986) [Pubmed]
  5. Acute haemodynamic effects of endralazine in patients with coronary artery disease and stable angina pectoris. van der Wall, E.E., de Feyter, P.J., Res, J.C., Roos, J.P., van Engelen, C.L. Postgraduate medical journal. (1983) [Pubmed]
  6. Endralazine and acetylator phenotype. Meems, L., Bogers, W.A. Lancet (1983) [Pubmed]
  7. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect. Holmes, D.G., Bogers, W.A., Wideroe, T.E., Huunan-Seppala, A., Wideroe, B. Lancet (1983) [Pubmed]
  8. Hemodynamic effects of the arteriolar vasodilators hydralazine, dihydralazine and endralazine in the conscious spontaneously hypertensive rat. Struyker-Boudier, H.A., van Essen, H., Smits, J.F. Eur. J. Pharmacol. (1983) [Pubmed]
  9. Effects of intravenous endralazine in essential hypertension. Hoffmann, J.J., Thien, T., van T'Laar, A. British journal of clinical pharmacology. (1983) [Pubmed]
  10. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Meredith, P.A., Elliott, H.L., McSharry, D.R., Kelman, A.W., Reid, J.L. British journal of clinical pharmacology. (1983) [Pubmed]
  11. Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic. Chazan, B.I., Duff, D.A., McCallum, A., Whaley, K. Current medical research and opinion. (1986) [Pubmed]
  12. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period. Bogers, W.A., Meems, L. Eur. J. Clin. Pharmacol. (1983) [Pubmed]
  13. In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine). de Flora, S., Zanacchi, P., Bennicelli, C., Camoirano, A., Cavanna, M., Sciabà, L., Cajelli, E., Faggin, P., Brambilla, G. Environmental mutagenesis. (1982) [Pubmed]
  14. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile. Hauger-Klevene, J.H., Reader, C., Mayer, E., Sanchez, M.R. International journal of clinical pharmacology research. (1986) [Pubmed]
  15. A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension. Seedat, Y.K., Rawat, R. S. Afr. Med. J. (1984) [Pubmed]
  16. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Quyyumi, A.A., Wagstaff, D., Evans, T.R. Am. J. Cardiol. (1983) [Pubmed]
  17. Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function. Boehringer, K., Weidmann, P., Link, L., Bianchetti, M.G., Schiffl, H., Reubi, F.C. British journal of clinical pharmacology. (1983) [Pubmed]
  18. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine. Kindler, J., Rüegg, P.C., Neuray, M., Pacha, W. Eur. J. Clin. Pharmacol. (1987) [Pubmed]
  19. Tissue distribution of endralazine and its clinical effect in refractory hypertension. Kindler, J., Moedder, G., Sieberth, H.G. Contributions to nephrology. (1985) [Pubmed]
  20. Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine. Oates, H.F., Stoker, L.M. Clin. Exp. Pharmacol. Physiol. (1981) [Pubmed]
  21. Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine. Kirch, W., Axthelm, T. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
 
WikiGenes - Universities